TITLE

Therapeutic potency of IL2–caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease

AUTHOR(S)
S Shteingart
PUB. DATE
June 2009
SOURCE
Gut;Jun2009, Vol. 58 Issue 6, p790
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Inflammatory bowel disease (IBD) comprises primarily the two disorders – ulcerative colitis and Crohn’s disease – that involve deregulated T cell responses. The ever-increasing incidence rate of Crohn’s disease and ulcerative colitis during recent decades, combined with the limited efficacy and potential adverse effects of current treatments, explain the real need for seeking more specific and selective methods for treating these diseases. AIM: To investigate the ability of interleukin 2 (IL2)–caspase 3 chimeric protein, designed to target activated T lymphocytes that express the high-affinity IL2 receptor, to ameliorate the clinical symptoms of acute murine experimental colitis, using a mouse model of dextran sodium sulfate (DSS)-induced colitis. METHODS: Mice with DSS-induced colitis were treated with IL2–caspase 3 for 7 days and disease severity was assessed in parallel to control, non-treated mice, receiving only daily injections of phosphate-buffered saline. IL2–caspase 3 was tested both for its ability to prevent the development of colitis, and for its therapeutic potential to cure on-going, active acute disease. In addition, colon tissue samples were used for myeloperoxidase assays and RNA isolation followed by polymerase chain reaction to determine mRNA expression levels of specific genes. RESULTS: Treatment with IL2–caspase 3 dose-dependently ameliorated the disease activity index (DAI) of mice colitis. We achieved up to 78% improvement in DAI with intravenous injections of 15 µg/mouse/day. Furthermore, IL2–caspase 3 decreased neutrophil and macrophage infiltration to the inflamed tissue by up to 57%. IL2–caspase 3 was proven as a therapeutic reagent in another model, where treatment begins only after disease onset. Here we demonstrated a 70% decrease in DAI when compared to non-treated sick mice. A reduction in mRNA expression levels of both IL1β and tumour necrosis factor α was found in lysates of total colon tissue of treated mice, as compared to sick, untreated mice. We also found that expression levels of Bcl2 were significantly decreased after treatment, while Bax was upregulated in comparison to non-treated mice. Moreover, the Bcl2/Bax ratio, which is elevated in both experimental colitis and in human Crohn’s disease, decreased dramatically after treatment. CONCLUSIONS: IL2–caspase 3 chimeric protein may provide a novel approach to the therapy of human IBD, and a possible suggested treatment for other pathological conditions that involve uncontrolled expansion of activated T cells.
ACCESSION #
39987808

 

Related Articles

  • Mucosal T Cell Proliferation and Apoptosis in Inflammatory Bowel Disease. Sturm, Andreas; De Souza, Heitor S. P.; Fiocchi, Claudio // Current Drug Targets;May2008, Vol. 9 Issue 5, p381 

    Both forms of inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC), represent prototypical conditions whose most salient features are the presence of chronic inflammation involving various parts of the intestinal tract and an increased risk of cancer, which is a...

  • Fenotipo e historia natural de la enfermedad inflamatoria intestinal en un centro de referencia en Medell�n-Colombia. Ba�os, Fabi�n Juliao; V�lez, Mario Hern�n Ruiz; Arango, Jos� Fernando Fl�rez; G�mez, Jorge Hernando Donado; Zuluaga, Juan Ignacio Mar�n; Arango, Claudia Monsalve; G�mez, Carlos Andr�s Jim�nez; Zapata, Yineth Agudelo; Velayos, Fernando S. // Revista Colombiana de Gastroenterolog�a;Jul2012, Vol. 25 Issue 3, p240 

    Worldwide the frequencies of inflammatory bowel disease, ulcerative colitis and Crohn�s disease have all increased. In our own environment it has become necessary to establish the epidemiology of these entities and to determine their clinical and endoscopic behavior. Methodology: This is a...

  • In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis. Bridger, S.; Lee, J.C.W.; Bjarnason, I.; Lennard Jones, J.E.; Macpherson, A.J. // Gut;Jul2002, Vol. 51 Issue 1, p21 

    Background and aims: Smoking tobacco has opposite effects on the different forms of inflammatory bowel disease (IBD). It predisposes to the development of Crohn's disease (CD) yet is associated with a reduced incidence of ulcerative colitis (UC). We have studied sib pairs discordant for both...

  • Inflammatory bowel disease. O'Malley, John; Spinks, Julian // Pulse;5/25/2011, Vol. 71 Issue 19, p16 

    The article presents questions and answers related to irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), including the diagnostic process of IBD, what drug therapy to treat Crohn's disease, and the risk of cancer with ulcerative colitis.

  • Inflammatory bowel diseases.  // Mayo Clinic Health Letter;Oct2001, Vol. 19 Issue 10, p1 

    Discusses inflammatory bowel diseases. Etiology; Difference between Crohn's disease and ulcerative colitis; Signs and symptoms; Diagnostic techniques; Cancer risks; Treatment strategies. INSET: Colon cancer risks..

  • Kallikrein-kinin system activation in Crohn’s disease: differences in intestinal and systemic markers Devani, Massimo; Cugno, Massimo; Vecchi, Maurizio; Ferrero, Stefano; Di Berardino, Federica; Avesani, Ettore Contessini; de Franchis, Roberto; Colman, Robert W. // American Journal of Gastroenterology;Aug2002, Vol. 97 Issue 8, p2026 

    OBJECTIVES:Observations in experimental models and in human ulcerative colitis suggest that activation of the kallikrein-kinin system plays a role in the pathogenesis of inflammatory bowel disease. The aim of this study was to assess activation of the plasma and tissue kallikrein-kinin system in...

  • Unlocking the secrets of IBD. SerVaas, Cory // Saturday Evening Post;Jan/Feb94, Vol. 266 Issue 1, p42 

    Presents interviews with seven inflammatory disease specialists. Case for cyclosporine; Tracing genetic links; Choosing the right treatment; Longevity, pregnancy and new drugs; Alternatives to lleostomy; Iron and IBD; What causes IBD? INSETS: Now in remission, by Patrick Perry.;A cse of the...

  • A population-based study of familial clustering of inflammatory bowel disease in Florence. Palli, Domenico; Saieva, Calogero; Trallori, Giacomo; Bardazzi, Gabrielle; D'albasio, Guiseppe; Milla, Monica; Galli, Monica; Tarantino, Ottaviano; Pacini, Franco // European Journal of Public Health;Mar1997, Vol. 7 Issue 1, p109 

    Presents a study that investigated familial clustering of inflammatory bowel disease (IBD) in Florence, Italy. Information on ulcerative colitis and Crohn's disease; IBD diagnosis; Methods used in the study; Results and discussion.

  • Inflammatory bowel disease. Veronesi, James // RN;May2003, Vol. 66 Issue 5, p38 

    Discusses two types of inflammatory bowel disease (IBD): Crohn's disease and ulcerative colitis. Common signs and symptoms; Theories on the role of the immune system in the development of IBD; Distinctions between Crohn's and ulcerative colitis; Medical management; Surgical intervention;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics